logo
Share SHARE
FONT-SIZE Plus   Neg

Cell Therapeutics Says UW's Neuro-Oncology Program Begins Patient Enrolment

Cell Therapeutics, Inc. (CTIC: Quote) on Tuesday said the University of Washington's School of Medicine, Departments of Neurology and Neurosurgery, Division of Neuro-Oncology has begun enrolling patients in a randomized phase II clinical study comparing the combination of OPAXIO (paclitaxel poliglumex, PPX, CT-2103) and radiation therapy, or RT, to the combination of temozolomide, or TMZ, and RT for patients with newly-diagnosed glioblastoma multiforme.

The study objective is to determine whether paclitaxel poliglumex and RT are likely to improve progression-free survival and overall survival compared to TMZ and RT. It will also evaluate neuro-cognitive function and toxicities of these therapies.

Glioblastoma multiforme or GBM is a poor-prognosis high-grade malignant brain tumor with an active gene called MGMT, which substantially decreases the effectiveness of standard therapy with TMZ.

This study is a multicenter trial initiated and led by the Neuro-Oncology department of the Brown University Oncology Research Group in Providence, Rhode Island. The first patient at UW recently has been enrolled.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Burger chain Shake Shack Inc. said late Thursday that it has priced its initial public offering of 5 million Class A shares at $21 per share, which is above the previously estimated price range of $17 to $19 per share. The shares are expected to begin trading on the New York Stock Exchange on Friday, January 30 under the ticker symbol "SHAK." Google reported a higher fourth-quarter profit, driven by a 15 percent increase in revenues and one-time gains from the sale of Motorola Mobile business, somewhat offset by stock-based compensation expense and foreign exchange losses. Quarterly earnings and revenue missed Wall Street estimates, as ad revenues came under pressure. Online retailer Amazon.com, Inc. said Thursday after the markets closed that its fourth quarter fell 10.5% from last year, as higher expenses more than offset a 15% increase in sales. However, the company's quarterly earnings per share came in well above analysts' expectation, but its quarterly sales fell short of analysts' forecast.
comments powered by Disqus
RELATED NEWS
Trade CTIC now with 
Follow RTT